May 8, 2025 4:01 pm EDT Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
May 7, 2025 7:00 am EDT Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Apr 15, 2025 7:00 am EDT Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Mar 20, 2025 4:01 pm EDT Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update